Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions

James Olen Armitage, D. D. Weisenburger, M. Hutchins, D. F. Moravec, M. Dowling, S. Sorensen, J. Mailliard, J. Okerbloom, P. S. Johnson, D. Howe

Research output: Contribution to journalArticle

132 Scopus citations


Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73% of the patients achieved a CR. Twenty-six of the 37 CRs (70%) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80% v 40% at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalJournal of Clinical Oncology
Issue number2
Publication statusPublished - Jan 1 1986


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this